Cronos Group Q2 net revenue $15.6M (+58% YoY); gross loss expands to $15.8M; invests $110M in PharmaCann

Cronos Group Inc.

Net revenue $15.6M, up 58% YoY; ROW segment $13.4M (+74%) driven by Canada adult-use and Israel medical.
Gross loss $15.8M (from $2.9M loss); inventory write-downs $12M; Adj EBITDA loss $49.8M.
Strategic investment: option to acquire ~10.5% stake in PharmaCann for ~$110.4M, with commercial agreements.
Amended Ginkgo Bioworks agreement; commenced commercial-scale CBG production in June 2021.
Appointed Kendrick Ashton Jr. to Board; new Head of Regulatory, Global Head of Audit, VP Controller.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.